Skip to content

IMMX - Immix Biopharma, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchI

Immix Biopharma Inc

IMMX · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

I

IMMXImmix Biopharma Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 20

52-wk high: $13.19
52-wk low: $1.94
Prev close: $7.80
Mkt cap: $840.8M
Beta: 0.11
P/B: 3.5x

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$116.8M

MI
Millennium
Israel Englander · Q2 2026 13F
$21.3M
position
MW
Marshall Wace
Q2 2026 13F

Earnings

Reported Aug 7, 2026

Earnings came in 5.9% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $841M

Valuation

P/B3.52

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: IMMX
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $840.75M
Beta: 0.11

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Profit margin

+0.0%

Op margin

+0.0%

ROE

-34.2%

$18.5M

position

CI

Citadel

Ken Griffin · Q2 2026 13F

$5.2M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for IMMX

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.18-5.9%

-$0.17 expected

Next report

What the street expects next

EPS expected

-$0.19

-$0.21 to -$0.17

Revenue expected

$0.00

4 analysts

Last 30 days

2up1down

Analysts raising estimates

Estimate drift

0.02

Change in 30 days

-34.2%

ROA-20.5%

Growth

Beta0.11